A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Clinical trial NCT02978482 · COMPLETED

Trial details

NCT number: NCT02978482
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Malignancy

Start date: 2016-12-01
Primary completion: 2018-01-28
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.